Medscape: Bictegravir Combo Shows Promise in HIV-TB Coinfection

12 January 2026

Medscape MedBrief

Twice-daily bictegravir/emtricitabine/tenofovir alafenamide resulted in high sustained viral suppression rates over 48 weeks in patients with HIV infection receiving rifampicin-based treatment for TB. The regimen was safe and well tolerated, with no discontinuations or drug switches due to adverse events.

Read the full MedBrief here.

* The MedBrief was created using several editorial tools, including AI, as part of the process. Human editors reviewed the content before publication.

Source: Medscape